PCVX Trading Analysis - 10/06/2026 01:01 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge of PCVX (Vaxcyte Inc.) and are provided as external context only, separate from the data-driven analysis below.

• Vaxcyte reported positive Phase 3 data for its adult pneumococcal conjugate vaccine candidate (VAX-31) in prior quarters, supporting long-term pipeline optimism.
• Biotech sector saw renewed volatility amid FDA commentary on vaccine accelerated approval pathways, potentially impacting developmental names like PCVX.
• No confirmed near-term earnings date in this context, but fiscal year end is listed as 2025-12-01 with upcoming catalysts likely tied to trial readouts.
• Recent sector rotation into profitable large-caps may have pressured high-beta small/mid-cap biotech names, consistent with PCVX's beta of 1.53.
• Headlines suggest fundamental promise but binary event risk; this contrasts with the embedded data showing a sharp Oct 5 price spike and bearish options sentiment.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for PCVX as of 2026-10-06:

• Trailing P/E is 12.60, but trailing EPS is -7.62, indicating the company is not profitable and the P/E is derived from negative earnings (non-meaningful conventional valuation).
• Forward P/E, PEG ratio, price-to-book, total revenue, revenue growth, profit margins, ROE, and debt-to-equity are all null/unavailable in the data.
• Market cap is $9,854,611,125.00 with shares outstanding of 148,805,000.00 and institutional ownership at 81.81%.
• Dividend yield is 0.00% with no dividend rate or ex-dividend date.
• Beta is 1.53 (high volatility relative to market); 52-week high is $90.75, low is $39.87.
• Historical volatility is 83.09%; average volume is 2,192,000.00 vs 20-day volume avg of 1,569,592.00.
• No analyst consensus or target mean price provided (fields null).
• Fundamentals show a pre-revenue/early-stage biotech with heavy institutional backing; this diverges from the technical picture of a sudden gap to $73.34 and bearish options flow.

Current Market Position

Current price per indicators is $73.34 (2026-10-05 close). Minute bars show 2026-10-05 opened at $87.21, ranged $85.50–$90.75 early, then dropped to $84.00–$85.00 by 09:50, and daily history shows a low of $71.60 that day before closing $73.34 on volume of 12,900,942 (far above 20-day avg). On 2026-10-06 at 12:30, last bar close was $66.23 after trading as low as $65.36.

Key observation: price jumped from $56.16 (10-02) to $87.21 open on 10-05, then retraced hard. Recent intraday momentum on 10-06 is mildly up from $65.36 to $66.23 but overall post-spike weakness.

Technical Analysis

Price is well above all SMAs (5/20/50 aligned bullishly but stretched). RSI at 73.46 shows overbought momentum. MACD positive with histogram 0.10 (weak bullish). Bollinger upper is $66.11; price at $73.34 is outside upper band (expansion). 30-day range: price near top (high $90.75, low $55.09; current $73.34 is ~63% up the range).

True Sentiment Analysis (Delta 40-60 Options)

From tru-sentiment options data (2026-10-06 13:00):

Call Volume: $521,580.00 (21.0%) Put Volume: $1,958,360.00 (79.0%) Total: $2,479,940.00

Sentiment is Bearish. Pure directional conviction (delta 40-60) shows 1,402 call contracts vs 3,630 put contracts. This suggests near-term downside expectations despite the overbought technicals. Divergence: technicals show bullish stretch, but options flow is firmly bearish (put-heavy).

Key Price Levels (Observational Only)